MUMBAI — Seasoned corporate affairs leader Aparna Thomas has announced her departure from global healthcare giant Sanofi, bringing an end to a distinguished 18-year tenure with the pharmaceutical major.
Thomas, who most recently served as the Global Corporate Affairs Lead – Insulins & Established Products, shared news of her exit via a professional update on LinkedIn, noting that she plans to take time to explore new avenues before embarking on her next professional chapter.
Two Decades of Leadership & Global Impact
Thomas joined Sanofi in 2008 and consistently scaled her responsibilities, transitioning from localized communication assignments to driving high-stakes global mandates from India:
-
Entry and Early Roles: She joined the organization in 2008 as Director of Communications, where she anchored the company’s brand reputation, media relations, and internal communication strategies during a period of significant regulatory shifts in the pharmaceutical sector.
-
Global Mandate: In her final role as Global Corporate Affairs Lead for the Insulins & Established Products portfolio, she steered international corporate affairs initiatives, managing stakeholder engagement and narrative building for Sanofi’s critical chronic care and legacy medicine verticals.
Reflecting on her nearly two-decade journey, Thomas stated:
“I am grateful for the opportunities that allowed me to grow beyond the scope of my role and contribute at a global level.”
Industry Context and Legacy
Thomas’s departure marks the exit of one of Sanofi India’s longest-serving corporate affairs architects. During her 18 years with the company, she played an integral role in navigating complex healthcare ecosystems, policy adjustments, and public health communications across therapeutic segments.
Her strategy of leading global portfolios directly out of India highlighted the growing importance of Indian leadership talent in steering international corporate affairs for multinational pharmaceutical corporations.
What’s Next: Thomas has indicated that she will take a deliberate sabbatical to evaluate new interests and professional opportunities before announcing her next corporate destination. Sanofi has not yet named a direct successor for her global corporate affairs portfolio.
